Aflibercept (Eylea, BAY86-5321)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Choroidal Neovascularization
Conditions
Choroidal Neovascularization, Macular Degeneration
Trial Timeline
Jul 1, 2016 → Dec 13, 2019
NCT ID
NCT02821247About Aflibercept (Eylea, BAY86-5321)
Aflibercept (Eylea, BAY86-5321) is a pre-clinical stage product being developed by Bayer for Choroidal Neovascularization. The current trial status is completed. This product is registered under clinical trial identifier NCT02821247. Target conditions include Choroidal Neovascularization, Macular Degeneration.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06929143 | Pre-clinical | Active |
| NCT05705258 | Pre-clinical | Recruiting |
| NCT04519619 | Pre-clinical | Recruiting |
| NCT03939767 | Pre-clinical | Completed |
| NCT03290794 | Pre-clinical | Completed |
| NCT02821247 | Pre-clinical | Completed |
| NCT02800642 | Approved | Completed |
| NCT02425501 | Pre-clinical | Completed |
Competing Products
20 competing products in Choroidal Neovascularization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Everolimus + Ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab 0.5mg | Novartis | Phase 2 | 52 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal injection ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Intravitreal Pegaptanib | Pfizer | Pre-clinical | 22 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |